Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Trimmed by Wells Fargo & Company MN

Wells Fargo & Company MN lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,661 shares of the company's stock after selling 199,096 shares during the quarter. Wells Fargo & Company MN's holdings in Vir Biotechnology were worth $387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in Vir Biotechnology in the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. grew its position in Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after buying an additional 1,999 shares during the period. KBC Group NV raised its holdings in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc bought a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $74,000. Finally, Virtu Financial LLC bought a new position in shares of Vir Biotechnology in the fourth quarter worth approximately $94,000. 65.32% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the sale, the chief executive officer now owns 769,505 shares of the company's stock, valued at approximately $4,578,554.75. This represents a 9.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 99,611 shares of company stock worth $663,525 over the last 90 days. 15.60% of the stock is owned by insiders.

Vir Biotechnology Trading Down 0.4 %

Vir Biotechnology stock traded down $0.02 during midday trading on Wednesday, hitting $5.61. 1,264,463 shares of the stock were exchanged, compared to its average volume of 1,336,232. The stock's 50-day simple moving average is $6.44 and its 200 day simple moving average is $7.98. The stock has a market capitalization of $774.54 million, a price-to-earnings ratio of -1.43 and a beta of 1.36. Vir Biotechnology, Inc. has a fifty-two week low of $4.95 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. The Goldman Sachs Group cut their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $33.57.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).